Following our acquisition of oncology-supportive care medicine Sancuso^® in early 2022, we are pleased to report a successful second quarter and first half of the year.

Highlights from the quarter include:

• We released our 2021 Sustainability Report, detailing our activities pertaining to environmental, social and governance matters. As noted in the report: 
  • We provided 2.43 million doses of our products for patients,
  • We also safely disposed of over 6,200 pounds of expired or damaged products,
  • And no products were recalled and no clinical trials were terminated due to failure to practice good clinical standards.

• We welcomed Martin Brown Jr., attorney at Adams and Reese LLP, to our board of directors. Martin is an attorney at Adams and Reese LLP. His experience includes 10 years on the board of Brown Forman Corporation, the large American spirits and wine company whose shares are listed on the New York Stock Exchange. Martin brings significant legal, public company, health care and civic experience to our board. We know his contributions will be valuable in our efforts to acquire, develop and deliver innovative products to improve the quality of care for patients.

• This June, the American Journal of Respiratory and Critical Care Medicine published preclinical studies that support the use of our ifetroban candidate as a promising therapeutic for patients with pulmonary fibrosis associated with lung disease. We’re designing a new clinical program for this indication.

Thank you to our Cumberland team for their support and hard work during this quarter. We are pleased with the developments the second quarter has brought and look forward to sharing more updates throughout the remainder of the year.